Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)

AIDS

Volumn 22, Issue 11, 2008, Pages 1313-1322

  Autran, Brigitte ^a,b,c   Murphy, Robert L ^a,b,d   Costagliola, Dominique ^a,b,c   Tubiana, Roland ^a,b,c   Clotet, Bonaventura ^e   Gatell, Jose ^f   Staszewski, Schlomo ^g   Wincker, Norma ^h   Assoumou, Lambert ^a,c   El Habib, Raphaelle ⁱ   Calvez, Vincent ^a,b   Walker, Bruce ^j   Katlama, Christine ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Private Foundation   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g GOETHE UNIVERSITY   (Germany)

^h ORVACS   (France)

ⁱ SANOFI PASTEUR   (France)

^j HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Canarypox; HIV; Therapeutic vaccine

Indexed keywords

ALVAC-HIV; ANTIRETROVIRUS AGENT; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PLACEBO; RECOMBINANT CANARYPOX VACCINE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION; VIRUS TITRATION; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 49849090609     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fdce94     Document Type: Article

References (40)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N EnglJ Med 1998; 338:853-860.
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:12-16.
3. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
4. Autran B, Carcelain G. AIDS. Boosting immunity to HIV - can the virus help? Science 2000; 290:946-949.
5. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 2001; 98:13288-13293.
6. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-241.
7. Strategies for Management of Antiretroviral Therapy (SMART) study group, El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4-guided Interruption of antiretroviral therapy. N Engl J Med 2006; 355:2283-2296.
8. Autran B, Debre P, Walker B, Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 2003; 3:503-508.
9. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-255.
10. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV infection and restoration by vaccine induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200: 701-712.
11. Martinez V, Costagliola D, Bonuelle O, N'Go N, Schnuriger A, Theodorou I, et al., and the ALT Study Group. Combination of HIV-1-specific CD4 Th1 responses and IgG2 antibodies is the best predictor for persistence of long-term non progression. J Infect Dis 2005; 191:2053-2063.
12. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006; 108:3834-3842.
13. 251 infection of macaques. Nat Med 2000; 6:1140-1146.
14. Tryniscewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, et al. Vaccination of macaques with long-standing SIVmac251 infection lowers viral set-point after cessation of therapy. J Immunol 2002; 169:5347-5357.
15. Lisziewicz J,Trocio J, Xu J, Whitman L, Ryder A, Bakare N, et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005; 19:35-43.
16. 3 CD4 T lymphocytes (AIDS Clinical Trials Groups 209 and 214). J Infect Dis 2000; 182:1357-1364.
17. Bostrom AC, Hejdeman B, Matsuda R, Fredriksson M, Fredriksson EL, Bratt G, et al. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Vaccine 2004; 22:1683-1691.
18. Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, et al. Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004; 22:2966-2973.
19. Kran AM, Sommerfelt MA, Sorensen B, Nyhus J, Baksaas I, Bruun JN, Kvale D. Reduced viral burden amongst high re-sponder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005; 23:4011-4015.
20. MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral 'blips'. Vaccine 2005; 23:2066-2073.
21. Tartaglia J, Excler JL, El Habibb R, Limbach K, Meignier B, Plotkin S, Klein M. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3):S291-S298.
22. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290-298.
23. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-1246.
24. Jin X, Ramanathan M Jr, Barsoum S, Deschenes GR, Ba L, Binley J, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002; 76:2206-2216.
25. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617.
26. Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meiffrédy V, Venet A, et al. HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides in patients treated early with HAART during primary infection: the ANRS 095 randomized study. Vaccine 2007; (in press).
27. Markowitz M, Jin X, Hurly A, Simon V, Ramratnam B, Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-643.
28. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005; 23:4292-4301.
29. Levy Y, Gahery-Segard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-286.
30. Levy Y, Durier C, Lascaux AS, Meiffrédy V, Gahéry- Ségard H, Goujard C, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413.
31. Kilby JM, Bucy RP, Midvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy. HIV-specific immunizations and IL-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006; 194:1672-1676.
32. ViardJ-P, Burgard M, HubertJ-B, Aaron L, Rabian C, Pertuiset N, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18:45-49.
33. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305:205-208.
34. Kaslow RA, Rivers C, Tang J, Bender TJ, Goepfert PA, El Habib R, et al. Polymorphisms in HLA class 1 genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001; 75:8681-8689.
35. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535-551.
36. 6cells/l. AIDS 2005; 19:287-294.
37. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Pérez-Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1 infected patients. AIDS 2007; 21:1384-1386.
38. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600.
39. AnaworanichJ, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39:523-529.
40. Achenbach CJ, Till M, Palella FJ, Knoll MD, Terp SM, Kalnins AU, Murphy RL. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. HIV Med 2005; 6:7-12.